Cover Image
市场调查报告书

难治性慢性淋巴球性白血病:全球临床实验趋势

Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品编码 299735
出版日期 内容信息 英文 235 Pages
订单完成后即时交付
价格
Back to Top
难治性慢性淋巴球性白血病:全球临床实验趋势 Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H2, 2016
出版日期: 2016年07月29日 内容信息: 英文 235 Pages
简介

本报告提供难治性慢性淋巴球性白血病的治疗药相关临床实验调查分析,提供您临床实验数及受验人数,各阶段及各方面状况,有潜力的企业,正在开发的治疗药信息,临床实验简介等信息。

本报告概要

各地区的临床实验情形

  • 各国临床实验数量和平均实验人数
    • 亚太地区主要5国的临床实验数量
    • 欧洲主要5国的临床实验数量
    • 北美主要国家的临床实验数量
    • 中东·非洲主要国家的临床实验数量
    • 中南美主要5国的临床实验数量

G7各国临床实验数量:癌症治疗药临床实验上难治性慢性淋巴球性白血病的比例

G7各国的各阶段临床实验数量

G7各国临床实验数量:各进展状况

E7各国临床实验数量:癌症治疗药临床实验上难治性慢性淋巴球性白血病的比例

E7各国的各阶段临床实验数量

E7各国临床实验数量:各进展状况

各阶段临床实验数量

  • 进行中的临床实验:各阶段

各进展状况临床实验数量

临床实验的目标达成情形

一定期间所采用的实验对像

赞助商类别的临床实验数量

有潜力的赞助商

难治性慢性淋巴球性白血病治疗药临床实验主要的参与企业

有潜力的药剂

临床实验简介概要

附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GDHC3637CTIDB

GlobalData's clinical trial report, "Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H2, 2016" provides an overview of Refractory Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Refractory Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top